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AbsTrACT
background previous studies have shown associations 
between the use of anticholinergics (ac) and cognitive 
performance in the elderly, considering ac as a 
homogeneous set of drugs. The present study aims to 
assess the relationship between exposure to ac drugs 
and cognitive performance in middle-aged adults 
according to ac potency and drug class.
Methods Our cross-sectional study used baseline 
data of 34 267 participants aged 45–70 from the 
consultants des centres d’examen de santé de la sécurité 
sociale (cONsTaNces) cohort. The cumulative exposure 
to ac was measured using national reimbursement 
databases over the 3-year period preceding assessment 
of cognitive performance. eight classes of ac drugs were 
differentiated. episodic verbal memory, language abilities 
and executive functions were evaluated by validated 
neuropsychological tests. analyses were controlled on 
lifestyle and health status variables.
results This study showed a negative association 
between overall cumulative ac exposure and cognitive 
performances after adjustment. The use of drugs with 
possible ac effect according to the anticholinergic 
cognitive Burden scale (acB-1 score) was only 
associated with executive functions. analyses of ac 
exposure across drug classes showed a negative 
association between the use of ac antipsychotics and all 
cognitive functions assessed. heterogeneous associations 
were found for the use of ac anxiolytics, ac opioids 
and ac drugs targeting the gastrointestinal tract or 
metabolism. We did not find significant associations 
between the use of antihistamines, antidepressants, 
cardiovascular system or other ac medications and 
cognitive function.
Conclusion association between ac drugs and 
cognitive performance was highly heterogeneous 
across drug classes; this heterogeneity will have to be 
considered by future studies.
InTroduCTIon
Anticholinergic (AC) drugs are extensively used to 
treat a broad range of medical conditions. A first 
group encompasses muscarinic receptor antago-
nists that block acetylcholine-mediated neurotrans-
mission in the smooth muscle, heart, central and 
peripheral nervous systems.1 This effect is expected 
to induce therapeutic benefits in various conditions 
such as Parkinson’s disease, overactive bladder 
syndrome and chronic obstructive airway diseases. 
For a second group, the therapeutic effect relies 
on other pharmacological properties and the AC 
potency is therefore unwanted. Among others, this 
group includes certain diuretics, antihistamines and 
psychotropic drugs (eg, antidepressants). For both 
groups, side effects vary depending on whether 
the targeted muscarinic receptors are peripheral 
(dryness of the mouth, constipation, dysuria and 
mydriasis),2 central (confusion, delirium, halluci-
nations, and memory impairments, especially in 
elderly patients) or both.3 4
The detrimental effects of AC drug use have 
been mainly studied in elders without dementia. 
In France, 7.5%–14% of them are prescribed AC 
drugs.5 6 Several observational studies have docu-
mented an association between AC drug use and 
cognitive impairment in elderly patients,7–10 some-
times with a dose–effect association.11 However 
for neurodegenerative diseases such as Alzheimer’s 
disease and other forms of dementia, the early 
symptoms develop gradually over the years as a 
result of progressive brain cell damage.12 Therefore, 
to identify potential contributors, exposures must 
be measured several years before symptom onset, 
that is, in middle age.
Moreover, most of these studies either focused 
only on drugs with marked AC effects or pooled 
all AC drugs, regardless of the level of their AC 
potency and drug class. Consequently, their find-
ings about specific AC effects are difficult to inter-
pret, as the most widely prescribed ACs have a low 
AC potency,13 and some drug classes (such as anxi-
olytics) can also exert non-AC-related effects on 
cognition.14 Thus, studies of associations between 
AC drug use and cognitive impairment should 
specifically consider the level of AC potency and 
the drug class.
The main objective of this population-based 
study was first to test the hypothesis that AC 
exposure may dose-dependently affect cognitive 
performances as early as 45 years of age. Another 
objective was to test whether this association varied 
according to the AC potency of the considered 
drugs and according to their drug class.
MATerIAls And MeThods
All participants gave written informed consent to 
participate in the present study.
study design and population
This population-based study relied on individ-
uals enrolled in the CONSTANCES cohort. 
CONSTANCES is a large (200 000 participants at 
the end of the recruitment planned early 2019), 
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population-based, prospective cohort composed of a randomly 
selected sample of adults living in France and aged 18–70 years 
at recruitment. The general design of CONSTANCES is detailed 
elsewhere.15 Briefly, eligible individuals were invited by mail and 
completed a self-administered questionnaire on lifestyle, health 
status, medical history, socioprofessional status and lifetime 
employment history. Each participant attended a health screening 
centre for a comprehensive evaluation including a physical 
examination and laboratory tests. Participants aged 45–70 years 
underwent a battery of cognitive tests.16 The CONSTANCES 
cohort is also linked to the electronic database of the French 
statutory health insurance administrative database.17
We included cohort participants enrolled between February 
2012 and June 2016 who were 45 or over at recruitment, and 
used data collected through baseline questionnaires, medical 
examination and cognitive tests; information about drugs used 
during the previous 3 years was extracted from the insurance 
administrative database to calculate the cumulative exposure to 
AC drugs.
AC drug exposure measurement
For each drug delivered, the following information was collected 
from the insurance database: drug name according to the 
Anatomical Therapeutic Chemical (ATC) classification, date the 
drug was dispensed and amount dispensed (number of packages, 
number of tablets per package or total volume for liquids, tablet 
strength or concentration for liquids) and route of administra-
tion.18 Total dose (in mg) dispensed at each prescription fill was 
computed by multiplying the number of tablets per package by 
tablet strength and by number of packages dispensed. Then, we 
calculated the standardised daily dose (SDD) for each prescrip-
tion fill by dividing the total dose dispensed by the defined daily 
dose (DDD, a reference dose defined by international experts 
from the WHO as the average dose recommended for the main 
indication in an adult weighing 70 kg, for each ATC-5th level 
code and route of administration).19 All medications prescribed 
by a physician (including medications-as-needed) were taken 
into account. Since DDDs are not available for eye-drops and 
topical steroids, these drugs were excluded from our analyses.
Finally, cumulative exposure was obtained as the total stan-
dardised daily dose (TSDD) for each participant by summing the 
SDDs for all ACs dispensed over the 3 years preceding the cogni-
tive testing. Participants were divided into five groups based on 
their TSDD: non-user, 1–90 days, 91–365 days, 366–1095 days 
(ie, 3 years) and more than 1095 days.11
We used the Anticholinergic Cognitive Burden (ACB) scale 
to characterise AC potency.20 21 A panel of healthcare experts 
assigned a score to each drug: ACB-1, possible AC effect on 
cognition based on in vitro results or affinity for muscarinic 
receptors but without relevant clinical evidence; and ACB-2 
or ACB-3, clinically documented AC effect on cognition, with 
ACB-3 indicating greater ability to cross the blood–brain barrier 
and to induce confusion.22 We assembled drugs with a clinically 
confirmed AC effect (ACB-2 and ACB-3) into a single category 
(ACB-2/3).
The potential role of the drug class on the association 
between cumulative AC exposure and cognitive performances 
was assessed by splitting AC drugs in several groups according 
to the third level of the ATC classification level. However, AC 
drugs targeting the gastrointestinal tract or metabolism and AC 
cardiovascular drugs were grouped according to the first level of 
the ATC classification to ensure sufficient group size.
Cognitive tests
Cognitive functions were evaluated under standard conditions 
by trained neuropsychologists using four well-recognised tests 
described in detail elsewhere.23
1. The Free and Cued Selective Reminding Test was chosen 
to assess episodic verbal memory. Sixteen items to be mem-
orised are shown on index cards in groups of four.24 The 
participant is asked to remember as many items as possible, 
first freely then in response to a cue (semantic category—
that is, the item to remember ‘grape’ corresponds to the 
semantic category ‘fruit’) if free recall fails. Trials are car-
ried out three times immediately after the learning phase 
then 20 min later. For this study, we considered both the 
immediate free recall score (sum of the number of items re-
trieved freely at the first three recall trials) and the delayed 
free recall score (number of items retrieved freely during 
the delayed trial).
2. Language abilities were assessed using verbal fluency tests.25 26 
We counted the number of items named by the participant in 
1 min in the ‘animals’ category (semantic fluency task) and 
starting with the letter R (phonemic fluency task).
3. The Digit Symbol Substitution Test (DSST) of the Wechsler’s 
Adult Intelligence Scale was used to assess psychomotor 
speed.27 Nine-digit symbol pairs are followed by a list of dig-
its. Under each digit, the participant must write the corre-
sponding symbol, as fast as possible, in 120 s.
4. The two parts of the Trail Making Test evaluate attention 
and visuospatial perception (TMT-A) and shifting abilities 
(TMT-B); the task is to connect with a pencil as fast as pos-
sible and in ascending order a sequence of 25 circles.28 29 
In part A, the circles contain only digits, whereas circles in 
part B contain digits alternating with letters. For this study, 
we used the following: (number of correct moves/total 
time)×10.
Covariates
The main confounding factors related to cognitive functions 
were taken into consideration.23 They were collected through a 
self-administered questionnaire and medical examination.
Sociodemographic variables were gender, age (in six 5-year 
groups) and education level (in six categories: no academic qual-
ification, certificate of primary or secondary education, GCE 
(General Certificate of Education) or A level, up to 4 years 
of university education, 5 years of university education, and 
master’s degree or higher).
The following lifestyle variables were used: living with versus 
without a partner, smoking status (never, past or current), alcohol 
consumption (none; moderate defined as three glasses or less per 
day for men, and two glasses or less per day for women; and 
excessive if above), physical activity (on a 7-point scale where 
0 indicated none and 6 a high level of activity) and body mass 
index (in four categories: underweight, <18.5; normal, 18.5–
25; overweight, 25–30; and obese, ≥30).
Finally, the following health variables were recorded: 
depression disorders assessed using the Center for Epidemi-
ological Studies-Depression scale with scores of 16 or greater 
indicating a high risk of depression,30 self-rated health (from 
1, very good, to 8, very bad), diabetes, respiratory disease 
(asthma and/or chronic obstructive pulmonary disease), 
cardiovascular diseases (myocardial infarction, high blood 
pressure, stroke, angina, peripheral arterial occlusive disease 
of the lower limbs), musculoskeletal disorders, hypercholes-
terolaemia and cancer.
copyright.














1109Ziad a, et al. J Neurol Neurosurg Psychiatry 2018;89:1107–1115. doi:10.1136/jnnp-2018-318190
Cognitive neurology
statistical analyses
Categorical variables were described as percentages and contin-
uous variables as means and SD. Cumulative exposure groups 
were compared using the χ2 test for categorical variables and 
analysis of variance for continuous variables, with α set at 0.05. 
Sociodemographic variables such as age, gender and education 
level are known to be associated with cognitive performances. 
For comparisons of cognitive scores, we therefore computed the 
adjusted z-scores for age, gender and education level for each 
cognitive test, using multivariable linear regression according to 
the Barona method.31 32
Univariate linear regression models were built to assess the 
effect of cumulative AC exposure on cognitive performances. 
For each cognitive test, the z-score was the dependent variable 
and cumulative exposure was the independent variable. In addi-
tion, for each model, we adjusted on lifestyle variables first, then 
on both lifestyle and health status variables.
Effect size has been defined as small, medium or large, for 
beta values of 0.2, 0.5 or 0.8 since difference in adjusted z-score 
means can be interpreted as an adjusted Cohen’s d.33
In secondary analyses, we developed multivariable linear 
regression models to evaluate associations between cumulative 
AC exposure and cognitive performances according to the level 
of AC potency, then according to the drug class (ATC classifica-
tion level).
We performed several sensitivity analyses for overall expo-
sure (1) according to age group (<65 vs 65+); (2) by excluding 
participants who had at least one delivery of antipsychotics; 
and (3) according to drug class but restricted to ACB-1 drugs.
Missing data (5.6% of the data) were handled using multiple 
imputations with chained equations (mice) package in the R 
project. The imputed data set was generated by performing 50 
imputation cycles.
All analyses were done using R V.3.3.2 (https:// cran. r- project. 
org/).
resulTs
Between February 2012 and June 2016, 37 304 participants with 
a mean age of 57.8 years undertook the cognitive tests. Study 
population corresponded to participants with available data to 
compute cognitive z-scores (N=34 267 participants presenting 
all cognitive z-scores). Table 1 shows the main characteristics of 
participants. During the 3-year period preceding inclusion, AC 
drugs were dispensed at least once to 16 172 (47.2 %) partici-
pants. For nearly two-thirds of these AC drug users, cumulative 
exposure was less than 3 months. Elderly, women and individ-
uals with low education levels were more likely to have a high 
cumulative AC exposure (table 1).
Table 2 shows the frequency of AC drugs dispensing across 
ACB scores and drug classes. Among AC drug users, 12 220 
(76%) received at least one ACB-1 drug, 822 (5%) at least one 
ACB-2/3 drug, and 3130 (19%) at least one drug in both ACB 
categories. Exposure to two or more different AC drugs was 
recorded for 52.4% of AC drug users (table 2). The distribution 
of AC drug classes by AC potency is detailed in online supple-
mentary e-table 1.
Table 3 shows the associations between cumulative AC expo-
sure and cognitive test z-scores. In univariate analyses, being 
exposed to ACs was negatively associated with all cognitive 
test z-scores for most of the exposure levels. In all the studied 
tests, the effect size increased with the cumulative AC expo-
sure (p trend <0.001). After adjustment for cofounders, this 
association remained highly significant—although smaller—for 
the executive function tests, that is, the DSST (β=−0.193 
(p<0.001)) and the TMT (A: β=−0.167 (p<0.001); B: 
β=−0.163 (p<0.001)) within individuals highly exposed to 
AC drugs (>3 years). The association with verbal fluency was 
no longer significant after adjustment. A significant association 
persisted for the episodic memory tests with a small effect size 
(immediate free recall: β=−0.103 (p=0.018); delayed free 
recall: β=−0.125 (p=0.004)). In addition, after adjustment, 
significant associations with a gradient were observed for the 
1–3 years and more than 3 years’ exposure levels in DSST and 
TMT-A (p trend <0.001). The results of sensitivity analysis 
according to age group (<65 vs 65+) are displayed in online 
supplementary e-table 2.
Cumulative exposure to ACB-2/3 drugs was associated 
with episodic memory, that is, delayed free recall (β=−0.360 
(p<0.001)) with a significant dose–effect (p trend <0.001), 
while cumulative exposure to ACB-1 drugs was associated with 
executive functions, that is, the DSST (β=−0.179 (p<0.001)) 
(table 4).
The association between cumulative exposure to AC drugs 
and cognitive scores was heterogeneous across AC drug classes 
(table 5). For executive functions, it was large among antipsy-
chotics (DSST, β=−0.658 (p<0.001); TMT-A, β=−0.590 
(p<0.001); TMT-B, β=−0.511 (p<0.001)), small and medium 
among drugs targeting the gastrointestinal tract or metabolism 
(DSST, β=−0.154 (p=0.17); TMT-A, β=−0.287 (p=0.01); 
TMT-B, β=−0.344 (p=0.002)), and small among anxio-
lytics (DSST, β=−0.197 (p=0.005); TMT-A, β=−0.176 
(p=0.01); TMT-B, β=−0.170 (p=0.01)) (table 5). For episodic 
memory, it was medium among antipsychotics (immediate free 
recall, β=−0.433 (p<0.001); delayed free recall, β=−0.493 
(p<0.001)) and small among opioids (immediate free recall, 
β=−0.161 (p=0.15); delayed free recall, β=−0.101 (p=0.37)) 
and anxiolytics (delayed free recall, β=−0.185 (p=0.01)). Only 
exposure to AC antipsychotic was associated with impaired verbal 
fluency (semantic fluency, β=−0.380 (p<0.001); phonemic 
fluency, β=−0.262 (p=0.009)). There was a significant dose–
effect in all cognitive scores for exposure to AC antipsychotics 
(table 5): for example, the effect size in DSST in the group >1 
year (β=−0.658 (p<0.001)) was almost twice that of the group 
<1 year (β=−0.347 (p<0.001)) (p trend <0.001). Of note, no 
significant association was found between exposure to AC anti-
histamines, AC antidepressants or AC drugs for the cardiovas-
cular system and cognitive performance.
In the sensitivity analysis after excluding participants with 
antipsychotics deliveries, we noted that the effect size of asso-
ciation between overall cumulative AC exposure and cognitive 
performance—for the most exposed participants (>3 years)—is 
almost halved compared with the analysis, taking into account 
participants with antipsychotics deliveries (online supplemen-
tary e-table 3).
Sensitivity analysis performed on ACB-1 drugs (online supple-
mentary e-table 4) shows very similar results with an important 
effect size of antipsychotics.
dIsCussIon
This cross-sectional study of 34 267 individuals aged 45–70 
demonstrated a negative association between overall cumu-
lative exposure to AC drugs and cognitive performance. 
This association was medium for executive functions (DSST, 
TMT-A and TMT-B) and less pronounced for episodic memory 
(immediate and delayed free recall). To our knowledge, the 
present study is the first reporting such an association in 
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Table 1 Characteristics of participants (n=34 267) by cumulative exposure to anticholinergic drugs
Variable n













Age (years) 57.8±7.1 57.4±7.2 57.7±7.1 59.1±7.1 59.2±7.0 <0.001
Male gender 16 157 50% 45% 42% 40% 45% <0.001
Education level
  No academic degree 1046 3% 3% 4% 5% 8% <0.001
  Certificate of primary or secondary education 11 277 31% 35% 35% 39% 42%
  GCE or A level 5877 17% 17% 17% 17% 16%
  1–4 years of university 7455 22% 21% 23% 20% 18%
  5 years of university 2828 9% 8% 7% 7% 6%
  Master’s degree or higher 5784 18% 16% 14% 13% 11%
Lifestyle variables
Living with a partner 26 047 78% 76% 74% 70% 65% <0.001
Smoking status
  Never 14 511 46% 43% 42% 43% 37% <0.001
  Current 4437 13% 14% 14% 15% 21%
  Former 13 772 41% 43% 43% 43% 43%
Alcohol consumption
  None 4266 13% 14% 16% 18% 23% <0.001
  Moderate 22 221 75% 73% 71% 68% 62%
  Excessive 3796 12% 13% 13% 15% 16%
Physical activity score (0: none, 6: high activity level) 4.8±1.5 4.7±1.5 4.6±1.6 4.4±1.6 4.2±1.7 <0.001
Body mass index 25.4±4.2 25.6±4.3 26.2±4.7 26.9±5.0 28.1±5.5 <0.001
Health status variables
Self-rated health status
  1 (very good) 2283 8% 6% 4% 2% 2% <0.001
  2 11 423 39% 35% 26% 20% 13%
  3 10 663 33% 33% 33% 31% 25%
  4 4424 11% 14% 19% 20% 23%
  5 2425 5% 8% 10% 17% 20%
  6 1191 3% 3% 5% 8% 13%
  7 188 0% 0% 1% 2% 3%
  8 (very bad) 39 0% 0% 0% 0% 1%
Depressive symptoms*
  Yes 6826 17% 22% 31% 37% 48% <0.001
Diabetes
  Yes 2104 9% 7% 9% 13% 18% <0.001
Respiratory disease
  Yes 3117 7% 9% 16% 20% 22% <0.001
Cardiovascular diseases
  Yes 7062 18% 19% 27% 37% 48% <0.001
Musculoskeletal disorders
  Yes 4903 13% 15% 17% 22% 20% <0.001
Hypercholesterolaemia
  Yes 7366 17% 23% 30% 37% 45% <0.001
Cancer
  Yes 3017 8% 9% 10% 12% 12% <0.001
Categorical variables are described as percentages and continuous variables as mean±SD.
*Defined as a score ≥16 on the Center for Epidemiological Studies-Depression scale.
GCE, General Certificate of Education.
middle-aged adults, consistent with what has been observed 
in older individuals, whether regarding impairments in exec-
utive functions,34 episodic memory35 and risk of dementia.6 11 
Another novel finding of our study is that association between 
exposure to AC drug and cognitive performance was highly 
heterogeneous across drug classes: the effect size was medium 
for antipsychotics and small for drugs targeting the gastroin-
testinal tract or metabolism, opioids and anxiolytics. More 
specifically, a substantial proportion of the initially reported 
association between overall cumulative exposure to AC drugs 
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Number of different ACs dispensed
  1 7690 (47%) 62% 21% 22% 12%
  2 4371 (27%) 26% 30% 28% 19%
  3 2246 (14%) 9% 24% 21% 23%
  4 1049 (7%) 2% 15% 14% 17%
  ≥5 816 (5%) 0% 10% 15% 29%
ACB score*
  1: possible AC effect 12 220 (76%) 84% 66% 57% 42%
  2 or 3: moderate or severe AC effect 822 (5%) 6% 3% 5% 4%
  Both 3130 (19%) 10% 31% 38% 54%
AC drug class* (ATC classification level)
  Antihistamines (R06A) 7882 43% 62% 56% 52%
  Opioids (N02A) 4983 30% 33% 30% 33%
  Alimentary tract and metabolism drugs (A) 4713 27% 34% 29% 34%
  Anxiolytic drugs (N05B) 4016 20% 33% 34% 42%
  Antidepressant drugs (N06A) 2051 4% 19% 37% 48%
  Cardiovascular system drugs (C) 950 2% 7% 20% 31%
  Antipsychotic drugs (N05A) 318 0% 2% 6% 18%
  Other AC drugs 3493 15% 35% 29% 34%
*At least one dispensed AC drug.
AC, anticholinergic drug; ACB, Anticholinergic Cognitive Burden scale; ATC, Anatomical Therapeutic Chemical classification system.
and cognitive performance seems ascribable to individuals 
exposed to AC antipsychotics.
strengths and limitations
To our knowledge, this is the first study assessing the associa-
tion between exposure to AC drugs and cognitive performance 
within such a young population. Most of the previous studies on 
AC drugs and cognition included individuals aged 65 or over, 
whereas this study included individuals aged 45–70 (mean age: 
57.8). In addition, this study combines high-quality data on both 
cognitive functions and exposure to AC drugs. A comprehen-
sive set of well-established cognitive tests was administered by 
neuropsychologists who were specially trained and monitored, 
while precise quantification of the doses of AC drugs used and 
limited impact of recall bias were possible using claims national 
reimbursement databases. Also, the large sample size provided 
enough statistical power for considering each drug class sepa-
rately contrary to most of the earlier observational studies 
which relied on analyses pooling all ACs regardless of drug 
class. In contrast, we studied the association between cumula-
tive exposure to ACs and cognitive performance according to 
their level of AC potency and their drug class and highlighted 
an important heterogeneity of this association across ACB scores 
and drug classes. Besides, we used a more precise approach than 
a simple computation of the AC burden, which does not take 
into account either the drug dosage or the duration of expo-
sure. Another strength of our study is the wide panel of variables 
collected on CONSTANCES participants, which allowed us to 
correct for many potential confounders associated with either 
cognitive performance or prescription of AC drugs. Finally, the 
dose–effect relationship provides an additional argument for 
discussing a causal association. In the literature, authors already 
used it and found a dose–effect association between AC drug use 
and cognitive performances.11
One of the limitations of our study is that AC exposure quanti-
fication was based on the amount of AC drugs dispensed and not 
on the amount actually taken by the participants. However, this 
bias may be limited for participants with regular prescriptions. 
Therefore, it is very unlikely to affect our findings. Another 
limitation is that we did not include AC drugs for which a DDD 
was not available, that is, ocular solutions and topical glucocorti-
coids. These drugs are mainly topical and accounted for only 3% 
of AC drugs dispensed to the study participants; consequently, 
their exclusion is unlikely to have a substantial effect on our 
results. Finally, non-refundable medicines were not taken into 
account due to the lack of available data in the reimbursement 
databases. Finally, because our study focuses on the side effects 
of treatments rather than efficacy, we have not corrected our 
results for multiple comparisons. This practice is consistent with 
the literature in observational epidemiology.36 However, given 
this point, it is possible that some of our results may be falsely 
positive, especially when the effect size is small.
Comparison with other studies
Previous studies investigating the association between exposure 
to ACs and cognitive performance were conducted in patients 
aged 65 years and over.7 8 10 37 However, focusing on elderly 
people may be associated with potential protopathic bias, notably 
with psychotropic drugs. Indeed, these drugs may be prescribed 
to treat the early symptoms of an underlying cognitive disease. 
Investigating this association within a younger population may 
reduce this protopathic bias.
Moreover, few studies made a distinction between drugs based 
on the level of AC potency.9 We chose to use the ACB scale, 
which was extensively used in studies on cognitive ageing, over 
other valid scales to categorise AC drugs.13 38 39 In two cohort 
studies,21 40 cognitive impairment was significantly associated 
with cumulative exposure to ACB-2/3 ACs but not to ACB-1 
copyright.
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Table 4 Relation between cumulative exposure to anticholinergic drugs over a 3-year period and z-scores on cognitive function tests according to 
anticholinergic potency, adjusted on lifestyle and health status variables (n=34 267)
Cumulative AC 
exposure 
episodic memory Verbal fluency executive functions
Immediate free recall delayed free recall semantic fluency Phonemic fluency dssT TMT-A TMT-b 
estimate (se)
 
estimated (se) estimate (se) estimate (se) estimate (se) estimate (se) estimate (se) 
 Adjustment on lifestyle† and health status variables‡
none ref  ref  ref ref  ref  ref  ref  
ACB-1§ <3 months −0.016 (0.012)  −0.010 (0.012) −0.020 (0.012) −0.002 (0.012) 0.002 (0.012)  −0.016 (0.012)  −0.014 (0.012)  
3–12 months −0.048 (0.020) *
−0.040 (0.020)
−0.030 (0.020) −0.011 (0.020)  −0.032 (0.020)  −0.027 (0.020)  −0.037 (0.020)  
1–3 years 0.041 (0.028)  −0.025 (0.028) −0.030 (0.028) 0.037 (0.028)  −0.047 (0.028)  −0.092 (0.028) ** −0.043 (0.028)  





 **  ***  **  
 
none ref   ref ref  ref  ref  ref  
ACB-2/3§ <3 months −0.028 (0.020)  −0.040 (0.020) −0.010 (0.020) −0.002 (0.020)  −0.013 (0.020)  0.047 (0.020) * 0.002 (0.020)  
3–12 months −0.090 (0.042) *
−0.110 (0.042)
* −0.070 (0.042) −0.026 (0.042)  −0.082 (0.041) * −0.025 (0.042)  −0.025 (0.042)  
1–3 years −0.141 (0.048) ** −0.150 (0.048) ** −0.050 (0.048) −0.081 (0.048)  −0.060 (0.047)  −0.026 (0.048)  −0.045 (0.047)  
>3 years −0.159 (0.109)  −0.360 (0.109) *** −0.090 (0.109) 0.138 (0.109)  −0.165 (0.108)  −0.034 (0.109)  −0.160 (0.108)  
P trend *** *** * 
Each value is the adjusted cognitive z-score difference between two groups.
P value and p trend: *0.01–0.05, **0.001–0.01, ***<0.001.
P trend: we tested whether there was an ordered relationship between categories of cumulative exposure to AC and cognitive performance (dose–effect).
†Lifestyle variables: living with a partner, smoking status, alcohol consumption, physical activity and body mass index.
‡Health status variables: self-rated health status, depressive symptoms, diabetes, respiratory diseases, cardiovascular diseases, osteoarticular disease, hypercholesterolaemia and cancer.
§Anticholinergic potency was assessed using the ACB scale, with scores of 2 and 3 (moderate to marked anticholinergic effect) collapsed into a single group (ACB-2/3).
AC, anticholinergic drug; ACB, Anticholinergic Cognitive Burden; DSST, Digit Symbol Substitution Test; ref, reference; TMT, A and B, Trail Making Test.
ACs, without precision concerning the AC exposure duration. In 
contrast, in our study, exposure to ACB-1 ACs was significantly 
associated with impaired cognitive performances, particularly 
those assessing executive functions. However, caution is advised, 
since the cognitive tests used in these two studies differed from 
those of our study. Nevertheless, the association between cogni-
tive impairment and exposure to ACB-1 AC drugs would be of 
considerable clinical relevance, since these drugs are the most 
widely prescribed ACs. Indeed, among the study participants, 
45% had been dispensed at least one ACB-1 AC during the 3 
years preceding their inclusion into the cohort against 12% of 
those who had been dispensed at least one ACB-2/3.
To our knowledge, this study is the first that assessed the asso-
ciation between exposure to AC drugs and cognitive perfor-
mance separately for each drug class. Pooling drug classes can 
increase statistical power but do not allow to study the associ-
ation between a given drug class and cognitive performance.41 
For example, in our study, no significant association was 
found between exposure to ACs among antihistamines, anti-
depressants, cardiovascular drugs and cognitive performance. 
In contrast, the effect size of this association was medium 
among antipsychotics, small among anxiolytics and opioids 
(for episodic memory), and medium among drugs targeting 
the gastrointestinal tract or metabolism (for executive func-
tions). Thus, the association between AC exposure and cogni-
tive performances varied markedly across drug classes. These 
variations may ensue from differences in AC potency, non-AC 
effects specific to each drug, and/or indications for prescribing 
AC drugs. For instance, evidence exists about impaired cogni-
tive function in antipsychotic users, but whether this finding 
was related to the drug class (ie, indication bias, schizophrenia 
is known to be associated with cognitive dysfunction) or to 
AC properties was not determined.42 Similarly, opioids and 
anxiolytics were found associated with an increased risk of 
dementia and Alzheimer’s disease, respectively, but the under-
lying mechanisms were also not elucidated.14 43
A major finding of our study is that the effect size of the associ-
ation between cumulative exposure to ACs and cognitive perfor-
mance was substantially smaller in the sensitivity analysis after 
excluding participants with filled prescription for antipsychotics. 
This finding suggests that AC antipsychotic drugs contributed 
for a large part in this association. However, whether this associ-
ation is mainly due to the AC properties of these drugs, to prop-
erties shared by all antipsychotic drugs (including those without 
AC properties) or to an indication bias remains to be clarified. 
The same issue arises for anxiolytics, drugs targeting the gastro-
intestinal tract and opioids.
Cognitive impairments (in episodic memory and executive 
functions) demonstrated by the earlier cited studies can lead 
to a marked deterioration in life quality and a possible shift 
to social disability. Given the early results of this study, practi-
tioners could not be encouraged to prescribe non-AC drugs at 
the expense of AC drugs since our analyses focused only on AC 
drugs. Future studies comparing drugs with and without AC 
effects within a given drug class may help distinguish between 
these potential explanations. Similarly, the eventual interven-
tion of the drug–drug interaction will have to be studied in 
subsequent works.
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ConClusIon
The impact of AC drugs on cognitive performance and dementia 
has been widely studied in elderly people. This study showed 
a negative association between overall cumulative AC exposure 
to AC drugs and cognitive performance in middle-aged adults, 
suggesting that this impact may be observed years before the 
onset of clinical symptoms. However, this association was highly 
heterogeneous across ACB scores and drug classes. Importantly, 
antipsychotic drugs contributed for a large part in this associa-
tion. Future studies should investigate in more details the specific 
involvement of AC properties on cognitive performance within 
each drug class.
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